Core Insights - First Mid Bancshares, Inc. reported solid financial performance for Q3 2025, with growth in net interest margin, loans, and deposits, alongside strategic operational changes [3][10]. Financial Performance - Net interest income for Q3 2025 was $66.4 million, up $2.5 million or 3.9% from Q2 2025, and increased by $8.8 million or 15.3% compared to Q3 2024 [5][6]. - The net interest margin was 3.80%, an increase of 8 basis points from the previous quarter, driven by higher yields on earning assets [7]. - Quarterly net income was $22.5 million, or $0.94 diluted EPS, with adjusted net income of $23.3 million, or $0.97 diluted EPS [10]. Loan and Deposit Growth - Total loans reached $5.82 billion, a quarterly increase of $57.0 million or 1.0%, and a year-over-year increase of $209.4 million or 3.7% [8][9]. - Total deposits were $6.29 billion, up $99.3 million or 1.6% from the prior quarter [12]. Asset Quality - The allowance for credit losses (ACL) was $72.9 million, with an ACL to total loans ratio of 1.25% [11]. - The ratio of non-performing loans to total loans was stable at 0.38%, with non-performing assets to total assets decreasing to 0.30% [11]. Non-Interest Income and Expenses - Non-interest income for Q3 2025 was $22.9 million, a slight decrease from the prior quarter, primarily due to losses on the sale of securities [13][14]. - Non-interest expenses totaled $57.1 million, an increase from $54.8 million in the previous quarter, driven by higher salaries and one-time costs related to branch closures [16][17]. Strategic Initiatives - The company completed the conversion of its core operating system and closed 8 full-service branches to enhance efficiency and align with digital banking trends [3][10]. - A pending acquisition of Two Rivers Financial Group, Inc. was announced, aimed at diversifying the company's footprint into Iowa [4][10]. Capital and Dividend - Tangible book value per share increased by 6.0% to $28.21 during the quarter [19]. - The Board of Directors declared a regular dividend of $0.25 per share, payable on December 1, 2025 [19].

Core Insights - The company AgEagle Aerial Systems Inc. (EagleNXT) has sold three eBee VISION drones to the U.S. Army's 1st Battalion, 4th Infantry Regiment, enhancing training capabilities at the Joint Multinational Readiness Center in Germany [1][2][4] Company Overview - EagleNXT is recognized as a leading provider of advanced drone and aerial imaging solutions, with a focus on delivering innovative unmanned aerial systems (UAS) tailored to the defense sector [5][6] - The eBee VISION drone is designed for superior performance, featuring high-resolution imaging, real-time data transmission, and a flight time of up to 90 minutes, which allows for realistic battlefield simulations [4][7] Industry Impact - The integration of eBee VISION drones into military training scenarios aims to enhance interoperability and readiness among multinational forces, reflecting the evolving needs of modern militaries [3][5] - The sale signifies EagleNXT's growing presence in the defense sector, with expectations for further opportunities to support military and government partners globally [5]

MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events: BIO-EUROPE, November 3-5Location: Viena Congress and Convention Center, Vienna, Austria LSX Investival Showcase Europe 2025, November 17Location: Old Billingsgate, London, United Kingdom Jefferies Global Healthcare Conferenc ...

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), a leading provider of wellness solutions for people on the go, today announced its partnership with Priority Pass, the world’s leading airport experiences program, is going global. What first launched in North America last year is now being expanded to key international airports across the Middle East and Europe, giving travelers more ways to take care of themselves mid-journey. Through the expanded collaborat ...

Financial Position - Evaxion A/S has raised a total of $7.2 million recently, with $4.5 million from an at-the-market offering and $2.7 million from the exercise of investor warrants [2][7] - The company now has sufficient cash to fund its operations and R&D programs into the second half of 2027, extending from the first half of 2027 [1][7] Debt Management - By the end of the second quarter of 2025, Evaxion had cash on hand of $14.7 million and a debt of $9.2 million [4] - The debt was reduced by $4.1 million through a debt-to-equity conversion agreement with the European Investment Bank in July 2025, enhancing the company's equity position [4] Operational Insights - Evaxion expects to incur an operational cash spend of $14 million in 2025 [4] - The recent exercises of investor warrants have decreased the number of outstanding warrants to purchase Evaxion American Depositary Shares (ADSs) by 1.0 million, leaving a total of 2.8 million outstanding warrants [3][7] Company Overview - Evaxion is a clinical-stage TechBio company that utilizes its AI-Immunology™ platform to develop vaccines targeting cancer, bacterial diseases, and viral infections [5] - The company is focused on creating novel personalized vaccines and has a pipeline addressing high unmet medical needs in infectious diseases [5]

Core Insights - Biomea Fusion, Inc. will present at ObesityWeek® 2025, showcasing preclinical data for its drug candidates BMF-650 and icovamenib [1][2] Group 1: Presentation Details - Biomea will present two posters on November 4, 2025, focusing on BMF-650's efficacy and the combination of icovamenib with semaglutide [3] - The abstracts from these presentations will be published in the peer-reviewed Obesity journal supplement [3] Group 2: Product Information - Icovamenib is a selective covalent inhibitor of menin, aimed at enhancing the function and quantity of insulin-producing beta cells, representing a potential non-chronic therapy for Type 2 Diabetes (T2D) [4] - BMF-650 is a next-generation oral small-molecule GLP-1 receptor agonist designed for obesity treatment, offering improved oral bioavailability and sustained receptor activation [5] Group 3: Company Overview - Biomea Fusion is focused on developing oral small molecule therapies for diabetes and obesity, addressing metabolic disorders that affect a significant portion of the global population [6]

Authorization Positions Company to Generate Non-Dilutive, Tax-Free Capital to Support Growth, Innovation, and Sustainable ExpansionBELVIDERE, NJ, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced that the New Jersey Economic Development Authority (NJEDA) has preliminarily approved the Company’s application ...

Agreement Strengthens Plug’s Global Portfolio of Utility-Scale Hydrogen and Sustainable Fuel DevelopmentsSLINGERLANDS, N.Y., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, today announced the execution of a binding supply agreement with Allied Biofuels FE LLC (ABF) for up to 2 gigawatts (GW) of Plug’s GenEco PEM electrolyzer systems. The agreement supports ABF’s development of sustainable aviation fuel (SAF), el ...

Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ETPRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report third quarter 2025 financial results on Thursday, November 6th, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and confe ...

All amounts in U.S. dollars unless otherwise stated TORONTO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Onex Partners announced today an agreement by Onex Partners V (“OP V”), together with other founding institutional equity partners in Convex Group Limited (“Convex”), to sell Convex to Onex Corporation (“Onex”) and American International Group, Inc. (“AIG”) for $7 billion. Stephen Catlin, Paul Brand and the Convex management team founded Convex in 2019 as a de novo insurer in partnership with OP V as well as seve ...